Скачать или смотреть Results of ENDURANCE (E1A11) phase III trial: KRd versus VRd for initial therapy of NDMM

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial

Bortezomib (btz) combined with lenalidomide (len) and dexamethasone (dex) (VRd) is a standard initial therapy for NDMM. Carfilzomib (cfz), a next-generation proteasome inhibitor, in combination with len-dex (KRd) has shown higher efficacy in phase II trials. This randomized phase III trial was designed to examine if KRd improves progression free survival (PFS) compared to VRd in NDMM (current results), and whether indefinite maintenance with len improves OS compared with two-year maintenance.

In this randomized phase 3 trial, KRd did not improve PFS compared with VRd in NDMM. A significantly higher rate of cardio-pulmonary and renal toxicity was observed with KRd, while neuropathy rates were higher with VRd. VRd remains the standard triplet induction regimen in standard and intermediate risk NDMM, and a suitable backbone for 4 drug combinations.

Clinical trial information: NCT01863550

Please subscribe to our channel!
Subscribe to International Myeloma Foundation: http://bit.ly/XlUtPE

Visit our website at: https://www.myeloma.org

Find us online:
Facebook:   / myeloma  
Google+: http://gplus.to/imfmyeloma
IMF on twitter: @IMFMyeloma (  / imfmyeloma  )
Dr. Durie on twitter: @BrianDurieMD (  / brianduriemd  )

Support the IMF! http://bit.ly/WskQHC
Category
Nonprofits & Activism
License
Standard YouTube License